<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460120</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 43</org_study_id>
    <nct_id>NCT02460120</nct_id>
  </id_info>
  <brief_title>Evaluation of the Archimedes™ System for Transparenchymal Nodule Access</brief_title>
  <acronym>EAST</acronym>
  <official_title>Evaluation of the Archimedes™ System for Transparenchymal Nodule Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Broncus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Broncus Medical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Archimedes System is an image-guided navigation system used to access tissue samples in&#xD;
      the lungs. This study is being conducted to confirm the performance of the Archimedes System&#xD;
      in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung&#xD;
      cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor&#xD;
      is conducted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Updates to device&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of biopsies yielding tissue sufficient for diagnosis</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The the number of nodules with at least one biopsy sufficient for a definitive tissue diagnosis divided by the number of nodules sampled by the Archimedes System.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure planning time</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The time from selecting the patient CT until the tunnel path has been selected, reviewed and exported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodule access time</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The time from the start of navigation until the sheath has been placed at the first biopsy target.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The total fluoroscopy time from the start of fused-fluoroscopic navigational guidance to the time the devices are removed from the point of entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient registration time</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The total time it takes to correlate the patient's position via fluoroscopy with the navigational guidance system.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Navigation and tissue sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Archimedes System</intervention_name>
    <description>The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs</description>
    <arm_group_label>Navigation and tissue sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 21-75 years at screening&#xD;
&#xD;
          2. Highly suspicious SPN, defined as distinct nodule with a diameter of ≥8mm in its&#xD;
             largest dimension&#xD;
&#xD;
          3. No known endobronchial tumor&#xD;
&#xD;
          4. Tumor located anywhere in parenchymal tissue &gt;1 cm from pleura and accessible&#xD;
             bronchoscopically through a POE.&#xD;
&#xD;
          5. Willing to participate in all aspects of study protocol for duration of study&#xD;
&#xD;
          6. Able to understand study requirements&#xD;
&#xD;
          7. Signs study-related informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindication to bronchoscopy, for example:&#xD;
&#xD;
               -  Untreatable life-threatening arrhythmias&#xD;
&#xD;
               -  Inability to adequately oxygenate the patient during the procedure&#xD;
&#xD;
               -  Acute respiratory failure with hypercapnia (unless the patient is intubated and&#xD;
                  ventilated)&#xD;
&#xD;
               -  Recent myocardial infarction&#xD;
&#xD;
               -  Previously diagnosed high-grade tracheal obstruction&#xD;
&#xD;
               -  Uncorrectable coagulopathy&#xD;
&#xD;
          2. Known coagulopathy&#xD;
&#xD;
          3. Platelet dysfunction or platelet count &lt; 100 x 103 cells/mm3&#xD;
&#xD;
          4. History of major bleeding with bronchoscopy&#xD;
&#xD;
          5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram&#xD;
&#xD;
          6. Moderate-to-severe pulmonary fibrosis&#xD;
&#xD;
          7. Severe emphysema or COPD: additional testing and PI consent is required&#xD;
&#xD;
          8. Bullae &gt;5 cm located in vicinity of target SPN&#xD;
&#xD;
          9. Any other severe or life-threatening comorbidity that could increase the risk of&#xD;
             bronchoscopic biopsy or ATV tunneling, for example:&#xD;
&#xD;
               -  ASA class &gt; 3&#xD;
&#xD;
               -  &gt; stage 3 heart failure&#xD;
&#xD;
               -  severe cachexia&#xD;
&#xD;
               -  severe respiratory insufficiency or hypoxia&#xD;
&#xD;
         10. Ongoing systemic infection&#xD;
&#xD;
         11. Contraindication to general anesthesia&#xD;
&#xD;
         12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents&#xD;
             (e.g. aspirin, clopidogrel) prior to procedure&#xD;
&#xD;
         13. Participation in any other study in last 30 days&#xD;
&#xD;
         14. Prior thoracic surgery on the same side of the lung as the SPN.&#xD;
&#xD;
         15. Breastfeeding women or females of childbearing potential with a positive pregnancy&#xD;
             test prior to the procedure or the intent to become pregnant during the study.&#xD;
&#xD;
         16. Life expectancy of less than one year.&#xD;
&#xD;
         17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy&#xD;
&#xD;
         18. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Nader, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Treatment Centers of America at Southwestern Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Southwestern Regional Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>October 30, 2019</submitted>
    <returned>November 21, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

